Pneumonia MedDRA version: 9.1 Level: HLT Classification code 10004048 MedDRA version: 9.1 Level: PT Classification code 10060946
Conditions
Interventions
Pharmaceutical Form: Powder and solvent for solution for infusion
INN or Proposed INN: Piperacillin and enzyme inhibitor
Concentration unit: g gram(s)
Concentration type: equal
Concentration number: 4
Sponsors
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients (age >18 years old) 2) radiological evidence of pneumonia, 2) at least two of the following criteria; fever >38C or hypothermia =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patients with community acquired pneumonia Patients with Hospital acquired pneumonia (onset after >72 h of hospitalization)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To verify if adherence to international recommendations for empirical treatment of healthcare-associated pneumonia (piperacillin/tazobactam OR imipenem/meropenem PLUS vancomycin OR linezolid PLUS ciprofloxacin OPPURE levofloxacin) is associated with a reduction of related in-hospital mortality rate.;Secondary Objective: To verify if adherence to international recommendations for empirical treatment of healthcare-associated pneumonia is associated with a reduction of in-hospital stay.;Primary end point(s): Intra-hospital mortality | — |
Countries
Italy
Outcome results
None listed